Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short term Debt (2018 - 2026)

Akebia Therapeutics has reported Short term Debt over the past 4 years, most recently at $17.5 million for Q4 2023.

  • Quarterly Short term Debt fell 45.31% to $17.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Dec 2023, down 45.31% year-over-year, with the annual reading at $17.5 million for FY2023, 45.31% down from the prior year.
  • Short term Debt was $17.5 million for Q4 2023 at Akebia Therapeutics, up from $8.0 million in the prior quarter.
  • Over five years, Short term Debt peaked at $98.2 million in Q2 2022 and troughed at $8.0 million in Q3 2023.
  • The 3-year median for Short term Debt is $32.0 million (2022), against an average of $51.7 million.
  • The largest YoY upside for Short term Debt was 45.31% in 2023 against a maximum downside of 87.87% in 2023.
  • A 3-year view of Short term Debt shows it stood at $97.5 million in 2021, then crashed by 67.19% to $32.0 million in 2022, then tumbled by 45.31% to $17.5 million in 2023.
  • Per Business Quant, the three most recent readings for AKBA's Short term Debt are $17.5 million (Q4 2023), $8.0 million (Q3 2023), and $24.0 million (Q2 2023).